Institut National De La Sante Et De La Recherche Medicale

Universitè De Montpellier

Centre Hospitalier Universitaire De Montpellier

Inserm (institut National De La Sante Et De La Recherche Medicale)

Inserm

Université De Montpellier I

Bernard Klein

Jérôme Moreaux

The present invention relates to a method of testing whether a patient suffering from multiple myeloma will respond or not to a combination treatment consisting of at least one histone deacetylase inhibitor (HDACi) with at least one DNA methyltransferase inhibitors (DNMTi) comprising: i) determining the expression level (ELi) of several genes G-Gselected from table A in a biological sample obtained from said patient ii) comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the HADMS score trough the following formula (I) wherein &#x3b2;i represent the regression &#x3b2; coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=&#x2212;1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) iv) comparing the score HADMS determined at step iii) with a predetermined reference value HADMSv) and concluding that the patient will respond to the combination treatment when the HADMS score is higher than the predetermined reference value HADMSor concluding that the patient will not respond to the combination treatment when the HADMS score is lower than the predetermined reference value HADMS. 

Methods for predicting response to HDACi/DNMTi combination in multiple myeloma

The present invention relates to a method of testing whether a patient suffering of myeloma will respond or not to a histone deacetylase inhibitor (HDACi) comprising: determining the expression level (ELi) of several genes G-Gselected from table A in a biological sample obtained from said patient comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the HAS score trough the following formula wherein &#x3b2;i represent the regression &#x3b2; coefficient reference value for the gene Gand Ci=1 if the expression of the gene G(ELi) is higher than the predetermined reference level (ELRi) or Ci=&#x2212;1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) comparing the score HAS determined at step iii) with a predetermined reference value HASv) and concluding that the patient will respond to the HDACi when the HAS score is higher than the predetermined reference value HASor concluding that the patient will not respond to the HDACi when the HAS score is lower than the predetermined value HAS. 

Methods for predicting multiple myeloma treatment response

Growing community of inventors

Montpellier, France

Bernard Klein